Tailored Drug Titration Using Artificial Intelligence
| 対象疾患 | Hypertension |
|---|---|
| 相 | 該当なし |
| スポンサー | Optima Integrated Health |
| ステータス | 完了 |
| 参加者数 | 165 名 |
| 介入（薬剤） | optima4BP |
| 開始日 | 2020年2月18日 |
| 完了日 | 2022年12月30日 |
| 結果公開日 | 2026年7月20日 |
概要
The purpose of the ARTERY Outcomes study is to compare optima-for-blood pressure (optima4BP), a clinical decision support system for hypertension (HTN) treatment optimization to standard of care in patients with essential HTN.
Systolic Blood Pressure [SBP] (mmHg) Measured Remotely [Time Frame: 0 - 6 Months]
| optima4BP | 17.5 ± 5 mmHg |
|---|---|
| Standard of Care (SOC) | 15.1 ± 3.5 mmHg |
| optima4BP | 7.8 ± 0.7 mmHg |
| Standard of Care (SOC) | 5.8 ± 1.1 mmHg |
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- A Community Health Worker Intervention to Address Adverse Pregnancy Outcomes — University of Alabama at Birmingham
- Improving Hypertension Medication Adherence for Older Adults — University of Arizona
- A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Ar — Actelion
- LiveSMART Trial to Prevent Falls in Patients With Cirrhosis — University of Michigan
- SPYRAL HTN-ON MED Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode R — Medtronic Vascular
- A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontro — AstraZeneca